RNF182

Summary

RNF182 (ring finger protein 182, HGNC:28522) is a protein-coding gene on chromosome 6p23, encoding E3 ubiquitin-protein ligase RNF182 (Q8N6D2). E3 ubiquitin-protein ligase that mediates the ubiquitination of ATP6V0C and targets it to degradation via the ubiquitin-proteasome pathway.

Enables ubiquitin-protein transferase activity. Involved in protein ubiquitination. Located in cytoplasm.

Source: NCBI Gene 221687 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 37 total
• Phenotypes (HPO): 3
• MANE Select transcript: NM_152737

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28522
Approved symbol	RNF182
Name	ring finger protein 182
Location	6p23
Locus type	gene with protein product
Status	Approved
Aliases	MGC33993
Ensembl gene	ENSG00000180537
Ensembl biotype	protein_coding
OMIM	621026
Entrez	221687

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 14 protein_coding

ENST00000420478, ENST00000423553, ENST00000471906, ENST00000488300, ENST00000488763, ENST00000537388, ENST00000537663, ENST00000544682, ENST00000867841, ENST00000867842, ENST00000913239, ENST00000913240, ENST00000913241, ENST00000958706

RefSeq mRNA: 4 — MANE Select: NM_152737 NM_001165032, NM_001165033, NM_001165034, NM_152737

CCDS: CCDS4531

Canonical transcript exons

ENST00000488300 — 3 exons

Exon	Start	End
ENSE00001232087	13974210	13974364
ENSE00001939557	13976909	13980310
ENSE00003849763	13924952	13925023

Expression profiles

Bgee: expression breadth ubiquitous, 192 present calls, max score 98.25.

FANTOM5 (CAGE): breadth broad, TPM avg 2.9207 / max 92.4309, expressed in 857 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
65964	2.4943	843
65963	0.2655	104
65965	0.1609	62

Top tissues by expression

248 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	98.25	silver quality
cortical plate	UBERON:0005343	96.70	gold quality
ganglionic eminence	UBERON:0004023	94.57	gold quality
cerebellar vermis	UBERON:0004720	91.47	gold quality
pons	UBERON:0000988	89.62	gold quality
lateral nuclear group of thalamus	UBERON:0002736	87.69	gold quality
ventricular zone	UBERON:0003053	87.57	gold quality
postcentral gyrus	UBERON:0002581	84.26	gold quality
anterior cingulate cortex	UBERON:0009835	83.60	gold quality
parietal lobe	UBERON:0001872	83.48	gold quality
Ammon’s horn	UBERON:0001954	83.34	gold quality
superior frontal gyrus	UBERON:0002661	83.34	gold quality
stromal cell of endometrium	CL:0002255	83.26	gold quality
dorsal plus ventral thalamus	UBERON:0001897	83.01	gold quality
cerebellum	UBERON:0002037	82.86	gold quality
cerebellar cortex	UBERON:0002129	82.22	gold quality
cerebellar hemisphere	UBERON:0002245	82.12	gold quality
Brodmann (1909) area 23	UBERON:0013554	81.74	gold quality
medulla oblongata	UBERON:0001896	81.71	gold quality
cerebral cortex	UBERON:0000956	81.56	gold quality
buccal mucosa cell	CL:0002336	81.53	gold quality
right hemisphere of cerebellum	UBERON:0014890	81.51	gold quality
neocortex	UBERON:0001950	81.17	gold quality
entorhinal cortex	UBERON:0002728	81.13	gold quality
medial globus pallidus	UBERON:0002477	80.95	gold quality
right frontal lobe	UBERON:0002810	80.89	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	80.67	gold quality
superior vestibular nucleus	UBERON:0007227	80.51	gold quality
secondary oocyte	CL:0000655	80.25	gold quality
frontal cortex	UBERON:0001870	80.04	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.08

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

111 targeting RNF182, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4262	100.00	73.26	3931
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3120-5P	100.00	65.56	965
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-128-3P	99.95	71.17	2484

Literature-anchored findings (GeneRIF, showing 3)

• E3 ubiquitin ligase RNF182 is highly expressed in macrophages and is specifically upregulated by Toll-like receptors (TLR) stimuli (TLR4, TLR3 and TLR9 agonists). Knockdown of RNF182 selectively amplifies TLR signaling by promoting the production of proinflammatory cytokines but not type I interferons in macrophages. (PMID:31432514)
• The Role of Tissue-Specific Ubiquitin Ligases, RNF183, RNF186, RNF182 and RNF152, in Disease and Biological Function. (PMID:32486221)
• RNF182 induces p65 ubiquitination to affect PDL1 transcription and suppress immune evasion in lung adenocarcinoma. (PMID:37249301)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	rnf182	ENSDARG00000061049
mus_musculus	Rnf182	ENSMUSG00000044164
rattus_norvegicus	Rnf182	ENSRNOG00000018070
drosophila_melanogaster	roq	FBGN0036621

Paralogs (5): RC3H2 (ENSG00000056586), RC3H1 (ENSG00000135870), RNF227 (ENSG00000179859), RNF224 (ENSG00000233198), RNF228 (ENSG00000288658)

Protein

Protein identifiers

E3 ubiquitin-protein ligase RNF182 — Q8N6D2 (reviewed: Q8N6D2)

Alternative names: RING finger protein 182, RING-type E3 ubiquitin transferase RNF182

All UniProt accessions (5): C9IZ30, C9JAJ3, C9JAK6, C9JVS8, Q8N6D2

UniProt curated annotations — full annotation on UniProt →

Function. E3 ubiquitin-protein ligase that mediates the ubiquitination of ATP6V0C and targets it to degradation via the ubiquitin-proteasome pathway. Also plays a role in the inhibition of TLR-triggered innate immune response by mediating ‘Lys’-48-linked ubiquitination and subsequent degradation of NF-kappa-B component RELA.

Subunit / interactions. Interacts with ATP6V0C.

Subcellular location. Membrane. Cytoplasm.

Tissue specificity. Up-regulated in neuronal cells subjected to cell death-inducing injuries, such as oxygen and glucose deprivation (at protein level). Could be up-regulated in Alzheimer disease brains. Highly expressed in innate immune organs such as lymph nodes and spleen and in immune cells such as macrophages and dendritic cells.

Domain organisation. The RING-type zinc finger domain is required for E3 ligase activity.

Pathway. Protein modification; protein ubiquitination.

RefSeq proteins (4): NP_001158504, NP_001158505, NP_001158506, NP_689950* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001841	Znf_RING	Domain
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR017907	Znf_RING_CS	Conserved_site
IPR042285	RNF182	Family
IPR047986	RNF182_RING-HC	Domain

UniProt features (8 total): transmembrane region 2, sequence variant 2, sequence conflict 2, chain 1, zinc finger region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N6D2-F1	70.67	0.20

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-983168	Antigen processing: Ubiquitination & Proteasome degradation
R-HSA-1280218	Adaptive Immune System
R-HSA-168256	Immune System
R-HSA-983169	Class I MHC mediated antigen processing & presentation

MSigDB gene sets: 112 (showing top): REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION, REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION, AREB6_03, TAL1ALPHAE47_01, MARTORIATI_MDM4_TARGETS_NEUROEPITHELIUM_DN, CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_DN, BACH2_01, TGTGTGA_MIR377, PETRETTO_LEFT_VENTRICLE_MASS_QTL_CIS_UP, TGANTCA_AP1_C, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, AACTTT_UNKNOWN, IK2_01, TAL1BETAE47_01

GO Biological Process (1): protein ubiquitination (GO:0016567)

GO Molecular Function (6): ubiquitin-protein transferase activity (GO:0004842), zinc ion binding (GO:0008270), ubiquitin protein ligase activity (GO:0061630), protein binding (GO:0005515), transferase activity (GO:0016740), metal ion binding (GO:0046872)

GO Cellular Component (2): cytoplasm (GO:0005737), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Class I MHC mediated antigen processing & presentation	1
Immune System	1
Adaptive Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
protein modification by small protein conjugation	1
ubiquitin-like protein transferase activity	1
transition metal ion binding	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
binding	1
catalytic activity	1
cation binding	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

478 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RNF182	RNF186	Q9NXI6	576
RNF182	RNF175	Q8N4F7	503
RNF182	TBC1D30	Q9Y2I9	491
RNF182	LHFPL2	Q6ZUX7	477
RNF182	ZNRF4	Q8WWF5	476
RNF182	GID4	Q8IVV7	470
RNF182	OCIAD2	Q56VL3	469
RNF182	RNF150	Q9ULK6	467
RNF182	ATP6V0C	P27449	462
RNF182	ARHGAP12	Q8IWW6	415
RNF182	A0A2R8Y4M4	A0A2R8Y4M4	397
RNF182	SLC39A6	Q13433	389
RNF182	NRIP3	Q9NQ35	385
RNF182	MATCAP2	Q8NCT3	380
RNF182	SYTL2	Q9HCH5	359

IntAct

12 interactions, top by confidence:

A	B	Type	Score
RNF182	UBE2N	psi-mi:“MI:0915”(physical association)	0.590
UBE2D1	RNF182	psi-mi:“MI:0915”(physical association)	0.560
UBE2K	RNF182	psi-mi:“MI:0915”(physical association)	0.560
UBE2L3	RNF182	psi-mi:“MI:0915”(physical association)	0.560
UBE2L3	RNF182	psi-mi:“MI:0915”(physical association)	0.000
RNF182	UBA1	psi-mi:“MI:0220”(ubiquitination reaction)	0.000

BioGRID (18): RNF182 (Two-hybrid), RNF182 (Two-hybrid), UBE2L3 (Two-hybrid), RNF182 (Affinity Capture-RNA), RNF182 (Two-hybrid), RNF182 (Affinity Capture-Western), PCDHB14 (Affinity Capture-Western), RNF182 (Affinity Capture-Western), RELA (Affinity Capture-Western), RNF182 (Proximity Label-MS), RNF182 (Affinity Capture-Western), RNF182 (Reconstituted Complex), RNF182 (Two-hybrid), RNF182 (Affinity Capture-RNA), UBC (Biochemical Activity)

ESM2 similar proteins: A6NCL7, A6NCQ9, A6QP29, A6QQV9, B1AVH7, B5DFA1, D2H0G5, D2H6Z0, D2H788, D3ZBM4, D4A723, E1C2W7, O95153, Q0QWG9, Q3SWY0, Q3T0Y9, Q3U0L2, Q3UV31, Q3V3A7, Q5RF77, Q60943, Q6INB3, Q6PGG2, Q7TNF8, Q7Z465, Q80TI1, Q810L3, Q8BG47, Q8BRJ3, Q8BXP5, Q8C0R7, Q8C432, Q8CEF8, Q8HYZ0, Q8N0U2, Q8N6D2, Q8N8N0, Q8NC24, Q8QZS5, Q8TED9

Diamond homologs: A0A7I2V3R4, D2H788, D3ZBM4, O70277, O75382, P0DH78, Q3SWY0, Q3UIW8, Q58EC8, Q68EV7, Q6INB3, Q8C432, Q8N6D2, Q8QZS5, Q96D59, Q9BRZ2, Q9R1R2, A6NIN4, Q9DCB3, Q13049, Q3T0Y9, Q6IMG5, Q8CH72, Q8K0W3, Q9FY48, Q9H0X6, Q9NXI6, A5D8S5, D2H6Z0, D4A723, E1C2W7, M0QZC1, O60858, P0CG21, Q11072, Q32L60, Q3UP44, Q4VGL6, Q5M7V1, Q5TC82

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
Ub:E2	“up-regulates activity”	RNF182	ubiquitination
RNF182	“down-regulates quantity by destabilization”	ATP6V0C	polyubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

37 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	32
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1065 predictions. Top by Δscore:

Variant	Effect	Δscore
6:13974363:GA:G	donor_gain	1.0000
6:13974365:G:GG	donor_gain	1.0000
6:13976907:A:AG	acceptor_gain	1.0000
6:13976908:G:GG	acceptor_gain	1.0000
6:13973330:T:G	donor_gain	0.9900
6:13973346:T:G	donor_gain	0.9900
6:13924482:ACC:A	donor_gain	0.9800
6:13931662:A:AG	acceptor_gain	0.9800
6:13974205:TCCA:T	acceptor_loss	0.9800
6:13974206:CCAGG:C	acceptor_loss	0.9800
6:13974207:CA:C	acceptor_loss	0.9800
6:13974208:AGGA:A	acceptor_loss	0.9800
6:13974360:TTAGA:T	donor_gain	0.9800
6:13974364:AG:A	donor_loss	0.9800
6:13974365:G:GA	donor_loss	0.9800
6:13974366:TAG:T	donor_loss	0.9800
6:13974368:GGTA:G	donor_loss	0.9800
6:13974369:G:C	donor_loss	0.9800
6:13976903:TTACA:T	acceptor_loss	0.9800
6:13976904:TACA:T	acceptor_loss	0.9800
6:13976905:ACAG:A	acceptor_loss	0.9800
6:13976906:CA:C	acceptor_loss	0.9800
6:13976907:A:C	acceptor_loss	0.9800
6:13976908:GAC:G	acceptor_gain	0.9800
6:13925020:CCAGG:C	donor_loss	0.9700
6:13925021:CAGGT:C	donor_loss	0.9700
6:13925022:AGGT:A	donor_loss	0.9700
6:13925023:GGT:G	donor_loss	0.9700
6:13925024:G:GC	donor_loss	0.9700
6:13925025:T:G	donor_loss	0.9700

AlphaMissense

1608 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:13977177:T:A	C20S	1.000
6:13977177:T:C	C20R	1.000
6:13977178:G:A	C20Y	1.000
6:13977178:G:C	C20S	1.000
6:13977179:C:G	C20W	1.000
6:13977184:T:A	I22N	1.000
6:13977184:T:C	I22T	1.000
6:13977184:T:G	I22S	1.000
6:13977186:T:A	C23S	1.000
6:13977186:T:C	C23R	1.000
6:13977187:G:A	C23Y	1.000
6:13977187:G:C	C23S	1.000
6:13977187:G:T	C23F	1.000
6:13977188:T:G	C23W	1.000
6:13977198:T:G	Y27D	1.000
6:13977199:A:C	Y27S	1.000
6:13977219:C:A	P34T	1.000
6:13977219:C:T	P34S	1.000
6:13977220:C:A	P34H	1.000
6:13977224:A:C	K35N	1.000
6:13977224:A:T	K35N	1.000
6:13977229:T:C	L37P	1.000
6:13977234:T:A	C39S	1.000
6:13977234:T:C	C39R	1.000
6:13977235:G:C	C39S	1.000
6:13977236:T:G	C39W	1.000
6:13977240:C:G	H41D	1.000
6:13977242:T:A	H41Q	1.000
6:13977242:T:G	H41Q	1.000
6:13977249:T:A	C44S	1.000

dbSNP variants (sampled 300 via entrez): RS1000004207 (6:13932037 C>G), RS1000012516 (6:13973423 G>A,T), RS1000107970 (6:13967328 GT>G), RS1000223739 (6:13948191 C>T), RS1000227378 (6:13979414 G>T), RS1000235828 (6:13949146 T>C), RS1000267218 (6:13943142 A>G), RS1000294328 (6:13923596 A>G), RS1000371833 (6:13954883 G>A,C,T), RS1000403078 (6:13930436 C>T), RS1000408428 (6:13972865 C>A), RS1000431146 (6:13955155 T>C), RS1000435565 (6:13930089 A>G), RS1000469913 (6:13979781 A>G), RS1000554873 (6:13978147 GA>G)

Disease associations

OMIM: gene MIM:621026 | disease phenotypes: MIM:603047, MIM:312080

GenCC curated gene-disease

Mondo (7): amblyopia (MONDO:0001020), microcephaly (MONDO:0001149), strabismus (MONDO:0003432), hyperopia (MONDO:0004891), allergic disease (MONDO:0005271), astigmatism (MONDO:0011284), leukodystrophy (MONDO:0019046)

Orphanet (1): Leukodystrophy (Orphanet:68356)

HPO phenotypes

3 total (3 of 3 shown, HPO-id order):

HPO	Term
HP:0000646	Amblyopia
HP:0000252	Microcephaly
HP:0000483	Astigmatism

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST001826_8	Lymphoma	6.000000e-07
GCST004605_27	Mean corpuscular hemoglobin concentration	6.000000e-18
GCST009391_749	Metabolite levels	8.000000e-07

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004528	mean corpuscular hemoglobin concentration
EFO:0010390	sphingomyelin 14:0 measurement

MeSH disease descriptors (6)

Descriptor	Name	Tree numbers
D000550	Amblyopia	C10.228.140.055; C10.597.751.941.073; C11.966.073; C23.888.592.763.941.073
D001251	Astigmatism	C11.744.212
D006956	Hyperopia	C11.744.479
D006967	Hypersensitivity	C20.543
D008831	Microcephaly	C05.660.207.620; C10.500.507.400.500; C16.131.621.207.620; C16.131.666.507.400.500
D013285	Strabismus	C10.292.562.887; C11.590.810

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	5
trichostatin A	increases expression, affects cotreatment, decreases expression	3
sodium arsenite	affects cotreatment, decreases expression, increases abundance, increases expression	2
Panobinostat	affects cotreatment, decreases expression	2
Air Pollutants	decreases expression, increases abundance, increases expression	2
Tretinoin	decreases expression	2
sotorasib	decreases expression, affects cotreatment	1
propionaldehyde	increases expression	1
sulforaphane	decreases expression	1
butyraldehyde	increases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
pentanal	increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ormosil	affects binding, increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
trametinib	affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1
MT19c compound	increases expression	1
NVP-BKM120	affects cotreatment, decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Aldehydes	increases expression	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Doxorubicin	increases expression	1
Manganese	affects cotreatment, decreases expression, increases abundance	1
Phthalic Acids	increases methylation	1
Polyethylene Glycols	affects binding, increases expression	1

Clinical trials (associated diseases)

277 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00094614	PHASE4	COMPLETED	Trial Comparing Daily Atropine Versus Weekend Atropine
NCT03109314	PHASE4	COMPLETED	Combining Donepezil With Perceptual Learning in Normal and Amblyopic Human The Effect of Donepezil on Perceptual Learning in Adult Amblyopia
NCT00461656	PHASE4	COMPLETED	Povidone-iodine Antisepsis for Strabismus Surgery
NCT01901588	PHASE4	COMPLETED	Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery
NCT02379546	PHASE4	COMPLETED	The Effect of Anaesthesia Depth on Oculo-cardiac Reflex
NCT03349515	PHASE4	COMPLETED	The Effect of Povidone-iodine Ophthalmic Surgical Prep Solution on Respiration in Children Undergoing Strabismus Surgery With General Anesthesia.
NCT04549844	PHASE4	UNKNOWN	Peribulbar Block for Prevention of Oculocardiac Reflex
NCT06035757	PHASE4	RECRUITING	The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery
NCT06560268	PHASE4	NOT_YET_RECRUITING	Low Flow Anesthesia in Children Undergoing Strabismus Surgery
NCT00347204	PHASE4	COMPLETED	Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK
NCT00455455	PHASE4	COMPLETED	Corneal and Conjunctival Sensitivity and Staining Study
NCT00937105	PHASE4	COMPLETED	Daily Wear Corneal Infiltrative Event Study
NCT01387360	PHASE4	COMPLETED	Presbyopic Supracor Treatment for Near Myopic/Hyperopic Pseudophakic Eyes
NCT01977807	PHASE4	UNKNOWN	A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser in Asian Eyes Using LASIK
NCT02071576	PHASE4	UNKNOWN	A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser Using LASIK
NCT02112968	PHASE4	UNKNOWN	A Prospective Safety and Effectiveness Study of a New High Repetition Rate Excimer Laser Using LASIK for the Correction of Ammetropia and Presbyopia
NCT03881670	PHASE4	COMPLETED	On-Eye Optical Quality of Lotrafilcon B Lenses Over 12 Hours
NCT04208750	PHASE4	COMPLETED	Clinical Investigation of the Vision-R800 Device.
NCT04283331	PHASE4	UNKNOWN	Anesthetic Impregnated Bandage Soft Contact Lens (BSCL) in Pain Management After Photorefractive Keratectomy (PRK)
NCT00000170	PHASE3	COMPLETED	Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia
NCT00001864	PHASE3	COMPLETED	Amblyopia (Lazy Eye) Treatment Study
NCT00038753	PHASE3	UNKNOWN	Vision In Preschoolers Study (VIP Study)
NCT00091923	PHASE3	COMPLETED	Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children
NCT00094679	PHASE3	COMPLETED	Trial Comparing Part-time Versus Minimal-time Patching for Moderate Amblyopia
NCT00094692	PHASE3	COMPLETED	An Evaluation of Treatment of Amblyopia in Children 7 To <18 Years Old
NCT00094744	PHASE3	COMPLETED	Trial Comparing Part-time Versus Full-time Patching for Severe Amblyopia
NCT00131729	PHASE3	COMPLETED	Electronic Recording of Compliance With Occlusion Therapy for Amblyopia
NCT00315198	PHASE3	COMPLETED	Trial Comparing Near Versus Distance Activities While Patching for Amblyopia in Children 3 to <7 Years Old
NCT00315302	PHASE3	COMPLETED	Trial Comparing Atropine to Atropine Plus a Plano Lens for the Sound Eye for Amblyopia in Children 3 to <7 Years Old
NCT00315328	PHASE3	COMPLETED	Trial Comparing Patching Versus Atropine for Amblyopia in 7 to < 13 Year Olds
NCT00506675	PHASE3	TERMINATED	Combined Patching-Atropine for Residual Amblyopia
NCT00525174	PHASE3	COMPLETED	Full-time Bangerter Filters Versus Part-time Daily Patching for Moderate Amblyopia in Children
NCT00587171	PHASE3	TERMINATED	Trial Comparing Patching With Active Vision Therapy to Patching With Control Vision Therapy as Treatment for Amblyopia
NCT00944710	PHASE3	COMPLETED	Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old
NCT00945100	PHASE3	COMPLETED	Increasing Patching for Amblyopia in Children 3 to < 8 Years Old
NCT01190813	PHASE3	COMPLETED	Levodopa for the Treatment of Residual Amblyopia
NCT04378790	PHASE3	RECRUITING	A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
NCT06380517	PHASE3	RECRUITING	Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
NCT06524882	PHASE3	RECRUITING	Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age
NCT00000128	PHASE3	UNKNOWN	A Trial of Bifocals in Myopic Children With Esophoria